DJIA 17,156.85 24.88 0.15%
NASDAQ 4,562.19 9.43 0.21%
S&P 500 2,001.57 2.59 0.13%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Grading Sobek's Mid-Year Biotech Stock Predictions

Sarepta Therapeutics (SRPT) Enters Oversold Territory - Tale of the Tape

Sarepta's Monday Selloff on New (Old) Worries Addressed

SRPT Crosses Below Key Moving Average Level

Short Interest is Piling Up in Sarepta Therapeutics (SRPT) Stock, Time to Panic? - Tale of the Tape

Why Wall Street is Betting Heavily Against Sarepta Therapeutics

Despite the FDA recently providing a regulatory pathway for Sarepta's Duchenne muscular dystrophy drug, the stock is still one of the most heavily shorted in health care. Here's why.

What You Need to Know About PTC Therapeutics' Promising DMD Drug

PTC Therapeutics (PTCT) won support from a key EU advisory committee last month, potentially clearing the way for a drug launch next year.

Tuesday’s Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology

Vanda Pharmaceuticals, Prosensa, and Clovis Oncology could all loom large in health care headlines this morning. Here’s why.

Prosensa to Seek U.S. Approval for DMD Drug

Surprising MS Drug Approval: Time to Buy?

The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.
See More Articles...